Mesoblast(MESO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MESO Mesoblast

Trading 04-09 14:59:17 EDT

14.53

+0.61

+4.38%

High15.00	Low14.10	Vol268.71K
Open14.17	D1 Closing13.92	Amplitude6.47%
Mkt Cap1.86B	Tradable Cap1.14B	Total Shares128.30M
T/O3.91M	T/O Rate0.34%	Tradable Shares78.65M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MESO","market":"US","secType":"STK","nameCN":"Mesoblast","latestPrice":14.53,"timestamp":1775761102148,"preClose":13.92,"halted":0,"volume":268711,"delay":0,"changeRate":0.04382183908045973,"floatShares":78649063,"shares":128296718,"eps":-0.73592,"marketStatus":"Trading","change":0.61,"latestTime":"04-09 14:59:17 EDT","open":14.17,"high":15,"low":14.1,"amount":3910655.98029,"amplitude":0.064655,"askPrice":14.54,"askSize":117,"bidPrice":14.52,"bidSize":27,"shortable":3,"etf":0,"ttmEps":-0.73592,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1775764800000},"marketStatusCode":2,"adr":1,"adrRate":10,"listingDate":1447390800000,"exchange":"NASDAQ","adjPreClose":13.92,"preHourTrading":{"tag":"盘前","latestPrice":13.92,"preClose":13.92,"latestTime":"07:26 EDT","volume":62,"amount":863.04,"timestamp":1775733962620,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":13.92,"preClose":13.92,"latestTime":"17:05 EDT","volume":57795,"amount":804505.95,"timestamp":1775682314805,"change":0,"changeRate":0,"amplitude":0.000718},"volumeRatio":1.035256,"impliedVol":0.6734,"impliedVolPercentile":0.588},"requestUrl":"/m/hq/s/MESO/tweets","defaultTab":"tweets","newsList":[{"id":"2626182261","title":"Assessing Mesoblast’s Valuation After FDA Clears New Ryoncil Trial In Duchenne Muscular Dystrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2626182261","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626182261?lang=en_us&edition=fundamental","pubTime":"2026-04-09 17:37","pubTimestamp":1775727454,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) is back in focus after the US Food and Drug Administration granted investigational new drug clearance for a registrational trial of Ryoncil in Duchenne muscular dystrophy, a high-need pediatric indication.\nSee our latest analysis for Mesoblast.\nDespite the FDA news and Ryoncil sales updates, recent trading has been choppy, with a 90 day share price return decline of 33.88%, even as the 3 year total shareholder return stands at 119.59%. At A$2.03, recent moves suggest...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/assessing-mesoblasts-valuation-after-fda-clears-new-ryoncil","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/assessing-mesoblasts-valuation-after-fda-clears-new-ryoncil","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","BK4139","BK4585","BK4588","BK7508","MSB.AU","MESO","BK7501","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625947672","title":"Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation","url":"https://stock-news.laohu8.com/highlight/detail?id=2625947672","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625947672?lang=en_us&edition=fundamental","pubTime":"2026-04-08 21:07","pubTimestamp":1775653620,"startTime":"0","endTime":"0","summary":"Mesoblast outlines commercial strategy to double net revenues as Ryoncil approaches US$100M net revenue milestone since launch last year  Showcases transformative blockbuster products for inflammatory","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/08/3270209/0/en/Mesoblast-R-D-Day-Features-Significant-Commercial-Progress-Platform-Innovation.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSC","BK4150","MSB","BK4097","BK4006","PRGS","BK4575","LU2065732104.USD","MESO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625123669","title":"Mesoblast's Duchenne Muscular Dystrophy Treatment Heads for US Registrational Clinical Trial; Shares Up Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2625123669","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625123669?lang=en_us&edition=fundamental","pubTime":"2026-04-08 17:32","pubTimestamp":1775640723,"startTime":"0","endTime":"0","summary":"Mesoblast  said late Tuesday the US Food and Drug Administration granted an investigational new drug clearance, enabling the company to directly proceed to a registrational clinical trial evaluating Ryoncil in Duchenne muscular dystrophy, a genetic disorder.The trial will randomize 76 patients aged five to nine years to either Ryoncil or placebo, plus standard of care.The company said the primary endpoint will be time-to-stand at nine months, a validated FDA endpoint for approval.Mesoblast shares were up 5.4% in premarket activity Wednesday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MESO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625108996","title":"Mesoblast Wins FDA Nod for Registrational Ryoncil Trial in Duchenne Muscular Dystrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2625108996","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625108996?lang=en_us&edition=fundamental","pubTime":"2026-04-08 10:52","pubTimestamp":1775616738,"startTime":"0","endTime":"0","summary":"Mesoblast Limited ( ($AU:MSB) ) has provided an announcement. Mesoblast has received U.S. FDA clearance to proceed directly to a registrational cli...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mesoblast-wins-fda-nod-for-registrational-ryoncil-trial-in-duchenne-muscular-dystrophy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mesoblast-wins-fda-nod-for-registrational-ryoncil-trial-in-duchenne-muscular-dystrophy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MESO","BK4588","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625790995","title":"Mesoblast Ltd - FDA Clears Ryoncil Ind for Registration Trial in Dmd","url":"https://stock-news.laohu8.com/highlight/detail?id=2625790995","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625790995?lang=en_us&edition=fundamental","pubTime":"2026-04-08 10:31","pubTimestamp":1775615482,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nFWN40Q12M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MSB.AU","BK7501","MESO","BK7067","BK7508","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625930007","title":"Mach Natural Resources, Mesoblast And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session","url":"https://stock-news.laohu8.com/highlight/detail?id=2625930007","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625930007?lang=en_us&edition=fundamental","pubTime":"2026-04-07 20:02","pubTimestamp":1775563320,"startTime":"0","endTime":"0","summary":"U.S. stock futures down, Nasdaq 100 falls over 100 points. Mach Natural Resources LP (MNR) shares dip 7.6% in pre-market trading.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/04/07/Display-Of-Stock-Market-Quotes.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/04/07/Display-Of-Stock-Market-Quotes.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/26/04/51676277/mach-natural-resources-mesoblast-and-other-big-stocks-moving-lower-in-tuesdays-pre-market-session","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/04/51676277/mach-natural-resources-mesoblast-and-other-big-stocks-moving-lower-in-tuesdays-pre-market-session","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["MNR","BK4171","BK4139","MESO","BK4213"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625933491","title":"Mesoblast Plans New Share Issue to Raise Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2625933491","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625933491?lang=en_us&edition=fundamental","pubTime":"2026-04-07 16:19","pubTimestamp":1775549942,"startTime":"0","endTime":"0","summary":"An announcement from Mesoblast Limited ( ($AU:MSB) ) is now available. Mesoblast Limited has notified the ASX of a proposed issue of 1,260,589 new ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mesoblast-plans-new-share-issue-to-raise-capital?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mesoblast-plans-new-share-issue-to-raise-capital?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MESO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625898634","title":"BRIEF-Mesoblast Says Ryoncil's Net Revenue For Quarter Increases To US$30.3M","url":"https://stock-news.laohu8.com/highlight/detail?id=2625898634","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625898634?lang=en_us&edition=fundamental","pubTime":"2026-04-07 10:35","pubTimestamp":1775529307,"startTime":"0","endTime":"0","summary":"BRIEF-Mesoblast Says Ryoncil's Net Revenue For Quarter Increases To US$30.3MApril 7 (Reuters) - Mesoblast Ltd MSB.AX:RYONCIL NET REVENUE FOR QUARTER INCREASES TO US$30.3MFurther company coverage: MSB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nFWN40P0N2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","MSB.AU","BK7067","BK4139","BK7501","MESO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625108983","title":"Mesoblast reports March quarter Ryoncil sales of $30.3M","url":"https://stock-news.laohu8.com/highlight/detail?id=2625108983","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625108983?lang=en_us&edition=fundamental","pubTime":"2026-04-07 09:10","pubTimestamp":1775524210,"startTime":"0","endTime":"0","summary":"Mesoblast (MESO) “announced Ryoncil net sales were $30.3 million for the quarter ended March 31, 2026.1 Strong sales in February and March offset h...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mesoblast-reports-march-quarter-ryoncil-sales-of-30-3m-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mesoblast-reports-march-quarter-ryoncil-sales-of-30-3m-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MESO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625983628","title":"Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2625983628","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625983628?lang=en_us&edition=fundamental","pubTime":"2026-04-07 09:03","pubTimestamp":1775523780,"startTime":"0","endTime":"0","summary":"Strong growth in February/March following January seasonality Net revenue approaches US$100M since launch NEW YORK, April  06, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/07/3268787/0/en/Ryoncil-Continues-Successful-First-Year-Launch-with-Net-Sales-of-US-30-3M-in-March-Quarter.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSC","BK4575","BK4139","BK4006","MSB","MESO","BK4150"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625998831","title":"Mesoblast Ltd - Ryoncil Net Revenue for Quarter Increases to US$30.3M","url":"https://stock-news.laohu8.com/highlight/detail?id=2625998831","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625998831?lang=en_us&edition=fundamental","pubTime":"2026-04-07 08:13","pubTimestamp":1775520794,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nFWN40P0N2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK7508","BK7067","BK7501","MSB.AU","MESO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622890358","title":"Mesoblast Earnings Call: Ryoncil Momentum, Pipeline Upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2622890358","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622890358?lang=en_us&edition=fundamental","pubTime":"2026-03-27 08:02","pubTimestamp":1774569720,"startTime":"0","endTime":"0","summary":"Mesoblast Limited (($AU:MSB)) has held its Q2 earnings call. Read on for the main highlights of the call. Mesoblast’s latest earnings call struck a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mesoblast-earnings-call-ryoncil-momentum-pipeline-upside?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mesoblast-earnings-call-ryoncil-momentum-pipeline-upside?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MESO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620009972","title":"Mesoblast CEO Granted Additional Options Following Shareholder Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2620009972","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620009972?lang=en_us&edition=fundamental","pubTime":"2026-03-20 14:35","pubTimestamp":1773988524,"startTime":"0","endTime":"0","summary":"Mesoblast Limited ( ($AU:MSB) ) has shared an announcement. Mesoblast has disclosed a change in the securities held by Chief Executive Dr Silviu It...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mesoblast-ceo-granted-additional-options-following-shareholder-approval?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mesoblast-ceo-granted-additional-options-following-shareholder-approval?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MESO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620207252","title":"Mesoblast Issues 3.25 Million Unquoted Options Under Employee Incentive Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=2620207252","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620207252?lang=en_us&edition=fundamental","pubTime":"2026-03-20 14:07","pubTimestamp":1773986851,"startTime":"0","endTime":"0","summary":"Mesoblast Limited ( ($AU:MSB) ) has shared an announcement. Mesoblast Limited has notified the market of the issue of 3,245,600 unquoted options un...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mesoblast-issues-3-25-million-unquoted-options-under-employee-incentive-scheme?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mesoblast-issues-3-25-million-unquoted-options-under-employee-incentive-scheme?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MESO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620015904","title":"Mesoblast Sets Inaugural R&D Day to Showcase Strategy, Ryoncil and Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2620015904","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620015904?lang=en_us&edition=fundamental","pubTime":"2026-03-18 07:10","pubTimestamp":1773789054,"startTime":"0","endTime":"0","summary":"Mesoblast Limited ( ($AU:MSB) ) just unveiled an update. Mesoblast will host its inaugural R&D Day in New York on April 8, 2026, featuring its seni...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mesoblast-sets-inaugural-rd-day-to-showcase-strategy-ryoncil-and-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mesoblast-sets-inaugural-rd-day-to-showcase-strategy-ryoncil-and-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MESO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619831199","title":"Mesoblast Discloses Director Gregory George’s Share and ADS Purchases in Early March 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2619831199","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619831199?lang=en_us&edition=fundamental","pubTime":"2026-03-13 18:56","pubTimestamp":1773399394,"startTime":"0","endTime":"0","summary":"Mesoblast ( ($MESO) ) just unveiled an update. On March 12, 2026, Mesoblast Limited reported to the U.S. Securities and Exchange Commission that it...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mesoblast-discloses-director-gregory-georges-share-and-ads-purchases-in-early-march-2026?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mesoblast-discloses-director-gregory-georges-share-and-ads-purchases-in-early-march-2026?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4141","MMAT","MESO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618122974","title":"Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast","url":"https://stock-news.laohu8.com/highlight/detail?id=2618122974","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618122974?lang=en_us&edition=fundamental","pubTime":"2026-03-12 07:21","pubTimestamp":1773271260,"startTime":"0","endTime":"0","summary":"NEW YORK, March  11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the appointment of Ter","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/11/3254223/0/en/Dr-Teresa-Montagut-Appointed-as-Clinical-Development-and-Medical-Affairs-Head-at-Mesoblast.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSB","MESO","BK4575","BK4139","BK4150","MSC","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618974118","title":"Mesoblast hires Regeneron veteran to lead clinical development and medical affairs","url":"https://stock-news.laohu8.com/highlight/detail?id=2618974118","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618974118?lang=en_us&edition=fundamental","pubTime":"2026-03-12 07:18","pubTimestamp":1773271089,"startTime":"0","endTime":"0","summary":"An update from Mesoblast Limited ( ($AU:MSB) ) is now available. Mesoblast has created a new role of Head of Clinical Development and Medical Affai...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mesoblast-hires-regeneron-veteran-to-lead-clinical-development-and-medical-affairs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mesoblast-hires-regeneron-veteran-to-lead-clinical-development-and-medical-affairs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MESO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618608472","title":"Mesoblast Director Gregory George Deepens Stake with US$16.4m Share Purchases","url":"https://stock-news.laohu8.com/highlight/detail?id=2618608472","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618608472?lang=en_us&edition=fundamental","pubTime":"2026-03-10 06:57","pubTimestamp":1773097079,"startTime":"0","endTime":"0","summary":"An announcement from Mesoblast Limited ( ($AU:MSB) ) is now available. Mesoblast director Gregory George has significantly increased his stake in t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mesoblast-director-gregory-george-deepens-stake-with-us16-4m-share-purchases?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mesoblast-director-gregory-george-deepens-stake-with-us16-4m-share-purchases?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MMAT","MESO","BK4141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618617137","title":"Cynata Therapeutics' Drug Candidate's Potential Reinforced by Mesoblast Results, Says Euroz Hartleys","url":"https://stock-news.laohu8.com/highlight/detail?id=2618617137","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618617137?lang=en_us&edition=fundamental","pubTime":"2026-03-09 14:37","pubTimestamp":1773038279,"startTime":"0","endTime":"0","summary":"Cynata Therapeutics'  acute graft-versus-host disease  drug candidate, CYP-001's potential has been reinforced by Mesoblast's  fiscal first half results, said Euroz Hartleys in a Monday note.Mesoblast's results showed its product, Ryoncil, which is a mesenchymal stem cell therapy approved by the US FDA for the treatment of paediatric , generated $49 million in net sales during the period and guided towards full-year net sales of $110 million to 120 million.CYP-001 is currently in a phase 2 trial, with topline results expected in June, the note added.The research firm believes that CYP-001 could attract significant commercial interest if it successfully replicates its Phase 1 results, which showed about 86% overall response rate at Day 28 versus about 62% for standard of care.Euroz Hartleys has maintained a speculative buy rating on Cynata Therapeutics with a price target of AU$0.90.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK7067","BK7508","BK7501","MSB.AU","CYP.AU","LENZ","BK4139","MESO","BK4539"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mesoblast.com","stockEarnings":[{"period":"1week","weight":-0.119},{"period":"1month","weight":-0.0979},{"period":"3month","weight":-0.2994},{"period":"6month","weight":-0.2402},{"period":"1year","weight":0.3878},{"period":"ytd","weight":-0.2284}],"compareEarnings":[{"period":"1week","weight":0.0317},{"period":"1month","weight":-0.0033},{"period":"3month","weight":-0.0196},{"period":"6month","weight":0.0352},{"period":"1year","weight":0.3616},{"period":"ytd","weight":-0.0087}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.004747},{"month":2,"riseRate":0.454545,"avgChangeRate":0.029971},{"month":3,"riseRate":0.454545,"avgChangeRate":0.148159},{"month":4,"riseRate":0.363636,"avgChangeRate":0.145274},{"month":5,"riseRate":0.5,"avgChangeRate":-0.027677},{"month":6,"riseRate":0.3,"avgChangeRate":-0.077641},{"month":7,"riseRate":0.6,"avgChangeRate":0.120859},{"month":8,"riseRate":0.2,"avgChangeRate":-0.055117},{"month":9,"riseRate":0.4,"avgChangeRate":0.04193},{"month":10,"riseRate":0.5,"avgChangeRate":-0.049086},{"month":11,"riseRate":0.8,"avgChangeRate":0.095285},{"month":12,"riseRate":0.545455,"avgChangeRate":0.005342}],"exchange":"NASDAQ","name":"Mesoblast","nameEN":"Mesoblast","securityTypeName":"DR","adrRate":"1:10"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mesoblast(MESO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mesoblast(MESO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mesoblast,MESO,Mesoblast股票,Mesoblast股票老虎,Mesoblast股票老虎国际,Mesoblast行情,Mesoblast股票行情,Mesoblast股价,Mesoblast股市,Mesoblast股票价格,Mesoblast股票交易,Mesoblast股票购买,Mesoblast股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mesoblast(MESO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mesoblast(MESO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction